Skip to main content

Advancing Efforts in Disease Interception

Ben Wiegand, global head of the World without Disease Accelerator at Janssen, the Pharmaceutical Companies of Johnson & Johnson, talks about efforts to prevent a disease or to identify it in its earliest stages for more effective treatments.

Uncertain

Welcome to Scientific American’s Science Talk, posted on February 27, 2020. I’m Steve Mirsky. On this episode:

[WIEGAND CLIP]

That’s Ben Wiegand. He received a doctorate in physical chemistry from Harvard. You may have seen bumper stickers that say, “Honk if You Passed P. Chem.” Wiegand is now the Global Head of the World without Disease Accelerator, the WWDA, at Janssen, the Pharmaceutical Companies of Johnson & Johnson, where he’s involved in multiple efforts to prevent disease or identify it in its earliest stages for more effective treatments. We spoke by phone.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


[WIEGAND SEGMENT]

That’s it for this episode. Get your science news at our Website (www.scientificamerican.com.), where we’re bringing you the latest news and insights about coronavirus.

And don’t forget to follow us on Twitter, where you’ll get a tweet whenever a new item hits the Web site. Our twitter name is @sciam. For Scientific American’s Science Talk, I’m Steve Mirsky. Thanks for clicking on us.

Advancing Efforts in Disease Interception